United Kingdom· GB-APID-43796111000001108
Sogroya 15mg/1.5ml solution for injection pre-filled pens
A somapacitan product containing somapacitan, registered in United Kingdom by Novo Nordisk Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Somapacitan is registered in 13 of 19 countries.
Countries holding a registration under ATC H01AC07 (somapacitan), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Somapacitan · ATC H01AC07
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Somapacitan
- Manufacturer
- Novo Nordisk Ltd
- Country
- United Kingdom (GB)
- ATC code
- H01AC07
- ATC class
- Somapacitan
- Defined daily dose
- 0.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5712249127831
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
303 interactions on record for somapacitan.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Somapacitan · interactions on record
303 records
- 2 severe
- 296 moderate
- 5 minor
Most severe, free to view
- OmeprazoleA02BC01moderate
- PantoprazoleA02BC02moderate
- LansoprazoleA02BC03moderate
- RabeprazoleA02BC04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Somapacitan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOGROYANovo Nordisk A/S, Bagsvaerd
- CanadaSOGROYANOVO NORDISK CANADA INC
- SwitzerlandSogroya 10 mg/ 1.5 ml, Injektionslösung im FertigpenNovo Nordisk Pharma AG
- SpainSOGROYA 10 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- FinlandSogroyaNovo Nordisk A/S
- BelgiumSogroya 10 mg/1.5 mlNovo Nordisk
- SwedenSogroya 10 mg/1,5 ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- United StatesSOGROYANovo Nordisk
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Sogroya
- Norway · Sogroya
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc516ad4-83a6-4068-8ef8-1c8e893e40bd GET /v1/drugs/dc516ad4-83a6-4068-8ef8-1c8e893e40bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "43796111000001108",
"desc": "Sogroya 15mg/1.5ml solution for injection pre-filled pens (Novo Nordisk Ltd)",
"form": "Solution for injection",
"vpid": "43907911000001101",
"source": "dmd",
"vtm_id": "898161005",
"strength": "10 mg",
"substance": "Somapacitan",
"ingredient": "Somapacitan",
"supplier_code": "2080301000001101"
}See everything about somapacitan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.